Madrigalв Dip Apr 2026

Madrigal continues to report positive results from its own clinical trials, including the trial.

: Experts believe the U.S. market has approximately 1.5 million diagnosed MASH patients, providing "plenty of room" for multiple treatments, including Madrigal’s Rezdiffra. Clinical & Operational Status MadrigalВ Dip

The "dip" was primarily triggered by releasing positive Phase 2b data for its drug efruxifermin in patients with compensated cirrhosis due to MASH (metabolic dysfunction-associated steatohepatitis). Madrigal continues to report positive results from its

: Akero's results showed the potential for cirrhosis reversal, which temporarily overshadowed Madrigal's market position. including and Piper Sandler

Investment firms, including and Piper Sandler , maintain a bullish outlook despite the price drop: